AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30717671 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the ORISCAV-LUX2 study (660 subjects)
Number of subjects: 1558
Study 30717671 — intervention group
Group type: COMPARATOR
Intervention: Non-participants (549 subjects)
Number of subjects: 1558
Study 27647855 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (2 mg monthly for 12 months)
Number of subjects: 416
Study 27647855 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (10 mg monthly for 12 months)
Number of subjects: 416
Study 27647855 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-b1mAb (50 mg monthly for 12 months)
Number of subjects: 416
Study 25406305 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 3445
Study 25406305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3445
Study 23913386 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/day telmisartan
Number of subjects: 148
Study 23913386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the 2-week run-in period)
Number of subjects: 148
Study 21306709 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia combined with dexamethasone 0.2mg/mL (group II)
Number of subjects: 60
Study 21306709 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia alone using bupivacaine 0.125% and fentanyl 1 μg/mL (group I)
Number of subjects: 60
Study 19254612 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA)
Number of subjects: 30
Study 19254612 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface hip arthroplasty
Number of subjects: 30
Study 19254612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17091415 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic cervical length measurement
Number of subjects: 282
Study 17091415 — intervention group
Group type: COMPARATOR
Intervention: Clinical digital examination (Bishop score)
Number of subjects: 282
Study 15577591 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intradermal injection of 99mTc nanocolloidal albumin (Nanocoll)
Number of subjects: 142
Study 11421501 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC), 600 mg effervescent tablets, once a day for 12 months
Number of subjects: 44
Study 11421501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9200056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group offered screening; specific details on dosage and duration not available.
Number of subjects: 0
Study 9200056 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving usual medical care; specific details on dosage and duration not available.
Number of subjects: 0
Study 8305994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive drug therapy
Number of subjects: 0
Study 8305994 — intervention group
Group type: COMPARATOR
Intervention: Moderate antihypertensive drug therapy
Number of subjects: 0
Study 8305994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study 8305994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 3828550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 30 mmHg
Number of subjects: 10
Study 3828550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 40 mmHg
Number of subjects: 10
Study 3828550 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-body negative pressure (LBNP) of 50 mmHg
Number of subjects: 10
Study 3828550 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 10
Study 3828550 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 10
Study 29793527 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education seminar
Number of subjects: 244
Study 29793527 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 244
Study 27479888 — intervention group
Group type: EXPERIMENTAL
Intervention: HCVAD plus ponatinib
Number of subjects: 110
Study 27479888 — intervention group
Group type: COMPARATOR
Intervention: HCVAD plus dasatinib
Number of subjects: 110
Study 24599482 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Dates program
Number of subjects: 1690
Study 24599482 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1690
Study 22525650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO 2:1 ratio
Number of subjects: 28
Study 22525650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO 3:1 ratio
Number of subjects: 28
Study 22525650 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO+PRO 4:1 ratio
Number of subjects: 28
Study 22525650 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 28
Study 19435644 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month supervised exercise program (TPAD-IC)
Number of subjects: 21
Study 19435644 — intervention group
Group type: COMPARATOR
Intervention: Normal medical therapy (CPAD-IC)
Number of subjects: 21
Study 17264145 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (Sal; 4 mg)
Number of subjects: 12
Study 17264145 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 12
Study 14760188 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin and GP IIb/IIIa inhibitors during PCI
Number of subjects: 49
Study 14760188 — intervention group
Group type: COMPARATOR
Intervention: Historical references utilizing unfractionated heparin
Number of subjects: 49
Study 11454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 0.5 mg daily
Number of subjects: 602
Study 11454883 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg daily
Number of subjects: 602
Study 11454883 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate 40 mg qid
Number of subjects: 602
Study 9743505 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol
Number of subjects: 17
Study 9743505 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol with vaginal micronized progesterone
Number of subjects: 17
Study 9743505 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 17
Study 9743505 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol alone and combined with progesterone
Number of subjects: 17
Study 9743505 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy (with and without progesterone)
Number of subjects: 17
Study 7920316 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous BMT
Number of subjects: 29
Study 7920316 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic BMT
Number of subjects: 29
Study 7920316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 3291084 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cathodic trypsin-like immunoreactivity
Number of subjects: 105
Study 3291084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic lipase
Number of subjects: 105
Study 3291084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic isoamylase
Number of subjects: 105
Study 7037037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (75 mg daily)
Number of subjects: 28
Study 7037037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7037037 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 28
Study 31650412 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART‐3RP intervention (8-session weekly group intervention delivered via videoconferencing)
Number of subjects: 53
Study 31650412 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WC)
Number of subjects: 53
Study 30308127 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g of milled flaxseed daily for 1 year
Number of subjects: 0
Study 30308127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30308127 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (flaxseed and placebo)
Number of subjects: 0
Study 28115461 — intervention group
Group type: EXPERIMENTAL
Intervention: Health questionnaire
Number of subjects: 775
Study 28115461 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of FH
Number of subjects: 775
Study 25727933 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular sutures
Number of subjects: 1264
Study 25727933 — intervention group
Group type: COMPARATOR
Intervention: Skin stapling
Number of subjects: 1264
Study 24706842 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 3
Study 24706842 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month regimens containing rifampicin or rifapentine
Number of subjects: 3
Study 24706842 — intervention group
Group type: COMPARATOR
Intervention: Placebo or alternative regimen
Number of subjects: 3
Study 22592094 — intervention group
Group type: COMPARATOR
Intervention: RBV 800 mg/day
Number of subjects: 400
Study 22592094 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV 1000/1200 mg/day
Number of subjects: 400
Study 23098286 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management-health promotion nurse intervention
Number of subjects: 570
Study 23098286 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 570
Study 17468681 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐Item Short Form Health Survey (SF‐12)
Number of subjects: 0
Study 17468681 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Enjoyment and Satisfaction Questionnaire (Q‐LES‐Q)
Number of subjects: 0
Study 17468681 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SF‐12 and Q‐LES‐Q
Number of subjects: 0
Study 14697462 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20, 40, and 80 mg/day
Number of subjects: 196
Study 14697462 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 196
Study 14697462 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin, Pravastatin, Lovastatin, Simvastatin
Number of subjects: 196
Study 11995751 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies and randomised clinical trials
Number of subjects: 0
Study 9649045 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 264
Study 9649045 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 264
Study 7984617 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymogen in multi‐modality treatment
Number of subjects: 33
Study 2656603 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements
Number of subjects: 50
Study 2656603 — intervention group
Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 50
Study 1065802 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 300 mg/day for 14 days
Number of subjects: 76
Study 1065802 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 210 mg/day for 14 days
Number of subjects: 76
Study 1065802 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrasanone 600 mg/day for 14 days
Number of subjects: 76
Study 30452728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings
Number of subjects: 8182
Study 30452728 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health effects pictorial warnings
Number of subjects: 8182
Study 30452728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial warnings with personal testimonials
Number of subjects: 8182
Study 28492868 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 14
Study 28492868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 7
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily filgrastim 5 µg/kg
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 6 mg on day 3
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim day 7
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily filgrastim
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple myeloma patients
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim vs. filgrastim
Number of subjects: 134
Study 25910537 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 134
Study 22495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung SBRT (Stereotactic body radiation therapy)
Number of subjects: 551
Study 22495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of fiducial markers
Number of subjects: 551
Study 22495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of planar imaging
Number of subjects: 551
Study 22495454 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of experience with lung SBRT
Number of subjects: 551
Study 21717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical traction with 30% of body weight (Group C)
Number of subjects: 96
Study 21717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical traction with 10% of body weight (Group A)
Number of subjects: 96
Study 21717993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical traction with 20% of body weight (Group B)
Number of subjects: 96
Study 19851916 — intervention group
Group type: EXPERIMENTAL
Intervention: Online, individually tailored counseling report
Number of subjects: 2872
Study 19851916 — intervention group
Group type: COMPARATOR
Intervention: Personalized but untailored generic report
Number of subjects: 2872
Study 19851916 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored reports
Number of subjects: 2872
Study 19851916 — intervention group
Group type: COMPARATOR
Intervention: Untailored reports
Number of subjects: 2872
Study 17701771 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 42
Study 17701771 — intervention group
Group type: COMPARATOR
Intervention: Low-dose hormone replacement therapy (HRT) - estradiol 1 mg/norethisterone acetate 0.5 mg daily
Number of subjects: 42
Study 15521894 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg
Number of subjects: 10
Study 15521894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11174186 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined surgical and medical treatment (unilateral endoscopic sinus surgery after pretreatment with oral prednisolone for 10 days and local nasal budesonide bilaterally for 1 month)
Number of subjects: 32
Study 11174186 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (oral prednisolone and local nasal budesonide)
Number of subjects: 32
Study 11174186 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (unilateral endoscopic sinus surgery)
Number of subjects: 32
Study 10405566 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with exacerbation of COPD
Number of subjects: 40
Study 10405566 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 40
Study 7822198 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant group sports program
Number of subjects: 60
Study 7822198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sports program)
Number of subjects: 60
Study 3127421 — intervention group
Group type: EXPERIMENTAL
Intervention: Humegon
Number of subjects: 0
Study 3127421 — intervention group
Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 0
Study 3127421 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrodin
Number of subjects: 0
Study 3127421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both preparations (Humegon and Pergonal)
Number of subjects: 0
Study 30725265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation in patients with central-predominant hypoventilation
Number of subjects: 44
Study 30725265 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation in patients with non-central-predominant hypoventilation
Number of subjects: 44
Study 31287184 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention using liquorice mouth wash
Number of subjects: 93
Study 31287184 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (sign language and video modeling)
Number of subjects: 93
Study 29166673 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 1021
Study 29166673 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 1021
Study 29166673 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 1021
Study 29166673 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1021
Study 26152519 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text pre-notification of questionnaire delivery
Number of subjects: 418
Study 26152519 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mail reminder
Number of subjects: 418
Study 26152519 — intervention group
Group type: COMPARATOR
Intervention: Postal reminder
Number of subjects: 418
Study 23196938 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-naive individuals
Number of subjects: 331
Study 23196938 — intervention group
Group type: EXPERIMENTAL
Intervention: Framingham Risk Score ≥ 6% per 10 years (N = 44)
Number of subjects: 331
Study 23196938 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing age, height, weight, small LDL particles, black race
Number of subjects: 331
Study 23196938 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of carotid artery lesions
Number of subjects: 331
Study 21587279 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyunsaturated acid mixture treatment for 10 weeks
Number of subjects: 0
Study 18203127 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable selection using Rubin's rules (RR)
Number of subjects: 0
Study 18203127 — intervention group
Group type: EXPERIMENTAL
Intervention: Stacked method combining multiply imputed data sets
Number of subjects: 0
Study 18203127 — intervention group
Group type: COMPARATOR
Intervention: Complete-case analysis
Number of subjects: 0
Study 17716435 — intervention group
Group type: EXPERIMENTAL
Intervention: PermaNet nets
Number of subjects: 200
Study 17716435 — intervention group
Group type: EXPERIMENTAL
Intervention: Yorkool nets
Number of subjects: 200
Study 17716435 — intervention group
Group type: EXPERIMENTAL
Intervention: A-Z nets
Number of subjects: 200
Study 17716435 — intervention group
Group type: COMPARATOR
Intervention: Conventionally treated nets (using K-O Tab tablets)
Number of subjects: 200
Study 12604518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil (100 mg tablet twice daily for 3 days)
Number of subjects: 163
Study 12604518 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (double-strength tablet [160/800 mg] twice daily for 3 days)
Number of subjects: 163
Study 11123502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (91 mg d-alpha-tocopherol)
Number of subjects: 520
Study 11123502 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg slow-release vitamin C)
Number of subjects: 520
Study 11123502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Vitamin E and C
Number of subjects: 520
Study 11123502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study 11123502 — intervention group
Group type: COMPARATOR
Intervention: Combination of Vitamin E and C vs. placebo
Number of subjects: 520
Study 9197299 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9487 at 0.75 mg/kg
Number of subjects: 30
Study 9197299 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9487 at 1.5 mg/kg
Number of subjects: 30
Study 9197299 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 9487 at 2 mg/kg
Number of subjects: 30
Study 8222176 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm retrograde cardioplegia (group 2)
Number of subjects: 163
Study 8222176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold crystalloid cardioplegia (group 1)
Number of subjects: 163
Study 8222176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold retrograde blood cardioplegia (group 3)
Number of subjects: 163
Study 3082774 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 4
Study 3082774 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 4
Study 3082774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 4
Study 3082774 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 4
Study 3082774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 30220622 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD or AVD
Number of subjects: 67
Study 30220622 — intervention group
Group type: COMPARATOR
Intervention: BEACOPP-14 or escalated BEACOPP
Number of subjects: 67
Study 27434092 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet enriched with arabinoxylan and resistant starch
Number of subjects: 19
Study 27434092 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre Western-style diet
Number of subjects: 19
Study 24529485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (LI) group using LISS-DP
Number of subjects: 141
Study 24529485 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 23132469 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheter
Number of subjects: 150
Study 23132469 — intervention group
Group type: COMPARATOR
Intervention: No catheter
Number of subjects: 150
Study 20447070 — intervention group
Group type: EXPERIMENTAL
Intervention: L-T3
Number of subjects: 10
Study 20447070 — intervention group
Group type: COMPARATOR
Intervention: L-T4
Number of subjects: 10
Study 17881144 — intervention group
Group type: EXPERIMENTAL
Intervention: RT+HT
Number of subjects: 114
Study 17881144 — intervention group
Group type: COMPARATOR
Intervention: RT
Number of subjects: 114
Study 16331394 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiological and neuropsychological studies in idiopathic RBD
Number of subjects: 0